Clinical trial results:

An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma Summary

EudraCT number	2019-001259-37
Trial protocol	Outside EU/EEA
Global end of trial date	09 July 2020
Results information	
Result version number	v1 (current)
This version publication date	31 December 2020
First version publication date	31 December 2020
Trial information	
Trial identification	

Sponsor protocol code	D3741C00012
Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03976869
WHO universal trial number (UTN)	-
Notes:	

Sponsors

Sponsor organisation name	AstraZeneca AB
Sponsor organisation address	Not applicable, Sodertalje, Sweden, SE-151 85
Public contact	Clinical Study Information Center, AstraZeneca, US 1 877 240 9479, Information.Center@astrazeneca.com
Scientific contact	Clinical Study Information Center, AstraZeneca, US 1 877 240 9479, Information.Center@astrazeneca.com

Notes:

Paediatric regulatory details

···· · · · · · · · · · · · · · · · · ·	
Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-001976-PIP02-18
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes
Natas	

Notes:

Results analysis stage	
Analysis stage	Final
Date of interim/final analysis	11 September 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 July 2020
Global end of trial reached?	Yes
Global end of trial date	09 July 2020
Was the trial ended prematurely?	No
N - +	*

Notes:

General information about the trial

Main objective of the trial:

Main objective of the study was to assess the pharmacokinetic (PK) profile of velsecorat (AZD7594) at steady state in adolescent subjects with asthma.

Protection of trial subjects:

The study protocol and all protocol amendments, all versions of the informed consent form (ICFs) and any other written information and/or materials provided to the subjects were submitted to an institutional review board (IRB) by the Investigator and approved by an IRB in writing before the study was initiated. This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)/ Good Clinical Practice (GCP), applicable regulatory requirements and the AstraZeneca policy on Bioethics. The Principal Investigator (PI) at each site ensured that subjects and their legally authorised representative, defined are their parents/legal guardians (caregiver), were given full and adequate oral and written information about the nature, purpose, possible benefit and risk of the study. The PI also notified subjects and caregivers that they were free to withdraw from the study at any time. The PI gave the subjects and caregivers the opportunity to ask questions and time to consider the information provided. Subjects and their legally authorised representatives were required to sign a statement of assent or informed consent, respectively, that met the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act requirements, where applicable, and the IRB or study centre.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 July 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 36
Worldwide total number of subjects	36
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	36
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 10 centres across United States from 24-Jul-2019 to 9-Jul-2020.

Pre-assignment

Screening details:

Total 59 subjects were screened, 12 subjects were screen failed before entering the wash-out period and 11 subjects were screen failed after having entered the wash-out period. Finally 36 subjects entered the Treatment period and received velsecorat.

Period 1	
Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	12-14 years

Arm description:

Subjects received oral inhalation of velsecorat (360 μ g, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days.

Arm type	Experimental
Investigational medicinal product name	Velsecorat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Oral use

Dosage and administration details:

Oral inhalation of velsecorat (360 μ g [delivered dose], via dry powder inhaler [DPI]) once daily multipledose for 15 to 16 days. One inhalation per day at the same time (± 30 minutes) every day.

· · ·	
Arm title	15-17 years

Arm description:

Subjects received oral inhalation of velsecorat (360 μg_{r} delivered dose, via DPI) once daily for 15 to 16 days.

Arm type	Experimental
Investigational medicinal product name	Velsecorat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Oral use

Dosage and administration details:

Oral inhalation of velsecorat (360 μ g [delivered dose], via DPI) once daily multiple-dose for 15 to 16 days. One inhalation per day at the same time (\pm 30 minutes) every day.

Number of subjects in period 1	12-14 years	15-17 years
Started	20	16
Completed	19	15
Not completed	1	1
Lost to follow-up	1	-
Withdrawal by parent/guardian	-	1

Baseline characteristics

Reporting groups	
Reporting group title	12-14 years
Reporting group description:	
Subjects received oral inhalation of velse	corat (360 µg, delivered dose, via dry powder inhaler [DPI])

once daily for 15 to 16 days.

15-17 years

Reporting group description:

Reporting group title

Subjects received oral inhalation of velsecorat (360 μg_{r} delivered dose, via DPI) once daily for 15 to 16 days.

Reporting group values	12-14 years	15-17 years	Total	
Number of subjects	20	16	36	
Age categorical				
Units: Subjects				
In utero	0	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	0	
Newborns (0-27 days)	0	0	0	
Infants and toddlers (28 days-23 months)	0	0	0	
Children (2-11 years)	0	0	0	
Adolescents (12-14 years)	20	0	20	
Adults (18-64 years)	0	0	0	
From 65-84 years	0	0	0	
85 years and over	0	0	0	
Adolescents (15-17 years)	0	16	16	
Age Continuous				
Units: Years				
arithmetic mean	12.8	15.9		
standard deviation	± 0.77	± 0.77	-	
Sex: Female, Male				
Units: Subjects				
Female	11	8	19	
Male	9	8	17	
Race (NIH/OMB)				
Units: Subjects				
American Indian or Alaska Native	0	0	0	
Asian	3	0	3	
Native Hawaiian or Other Pacific Islander	0	0	0	
Black or African American	5	5	10	
White	12	11	23	
More than one race	0	0	0	
Unknown or Not Reported	0	0	0	
Ethnicity (NIH/OMB)				
Units: Subjects				
Hispanic or Latino	10	4	14	
Not Hispanic or Latino	10	12	22	

Clinical trial results 2019-001259-37 version 1

End points

End points reporting groups			
Reporting group title	12-14 years		
Reporting group description:			
Subjects received oral inhalation of velse once daily for 15 to 16 days.	ecorat (360 µg, delivered dose, via dry powder inhaler [DPI])		
Reporting group title	15-17 years		
Reporting group description:			
Subjects received oral inhalation of velse days.	ecorat (360 $\mu g_{}$ delivered dose, via DPI) once daily for 15 to 16		

Primary: Maximum observed plasma concentration at steady state (Cmax,ss) at Day 15

End point title	Maximum observed plasma concentration at steady state
	(Cmax,ss) at Day 15 ^[1]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type Primary	
------------------------	--

End point timeframe:

```
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
```

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	16	11	
Units: pmol/L			
geometric mean (geometric coefficient of variation)	95.13 (± 80.7)	155.8 (± 76.4)	

Statistical analyses

No statistical analyses for this end point

Primary: Minimum observed plasma concentration at steady state within 0 to 12 hours (Cmin,ss) at Day 15

End point title	Minimum observed plasma concentration at steady state within
	O to 12 hours (Cmin,ss) at Day 15 ^[2]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the

analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type	Primary	
End point timeframe:		
Pre-dose and 15, 30 minutes, 2, 4, 6, 8,	12 hours post-dose at Day 15	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	15	11	
Units: pmol/L			
geometric mean (geometric coefficient of variation)	46.79 (± 63.4)	77.61 (± 70.8)	

Statistical analyses

No statistical analyses for this end point

Primary: Observed trough plasma concentration at end of dosing interval (τ) (Ctrough) at Day 15

End point title	Observed trough plasma concentration at end of dosing interval
	() (Ctrough) at Day 15 ^[3]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type Primary

End point timeframe:

Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	15	11	
Units: pmol/L			
geometric mean (geometric coefficient of variation)	50.33 (± 73.6)	72.77 (± 65.0)	

Statistical analyses

No statistical analyses for this end point

Primary: Time of maximum observed plasma concentration at steady state (tmax,ss) at Day 15

End point title	Time of maximum observed plasma concentration at steady
	state (tmax,ss) at Day 15 ^[4]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type	Primary
End point timeframe:	

Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	16	11	
Units: Hours			
median (full range (min-max))	0.25 (0.23 to 3.10)	0.50 (0.08 to 4.00)	

Statistical analyses

No statistical analyses for this end point

Primary: Area under the plasma concentration-time curve over a dosing interval (τ) at steady state (AUC τ) at Day 15

End point title	Area under the plasma concentration-time curve over a dosing
	interval () at steady state (AUC) at Day 15 ^[5]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type	Primary

End point timeframe:

Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	15	11	
Units: h*pmol/L			
geometric mean (geometric coefficient of variation)	1204 (± 76.8)	2131 (± 67.8)	

Statistical analyses

No statistical analyses for this end point

Primary: Area under the plasma concentration-time curve from time zero to 12 hours post-dose (AUC0-12) at Day 15

End point title	Area under the plasma concentration-time curve from time
	zero to 12 hours post-dose (AUCO-12) at Day 15 ^[6]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type	Primary
End point timeframe:	

Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	15	11	
Units: h*pmol/L			
geometric mean (geometric coefficient of variation)	733.6 (± 69.3)	1218 (± 70.7)	

Statistical analyses

No statistical analyses for this end point

Primary: Apparent total body clearance after extravascular administration at steady state (CLss/F) at Day 15

End point title

Apparent total body clearance after extravascular administration at steady state (CLss/F) at Day 15^[7]

End point description:

To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).

End point type	Primary
End point timeframe:	

Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was available for this end point.

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	15	11	
Units: Liter/hours			
geometric mean (geometric coefficient of variation)	493.0 (± 76.8)	278.5 (± 67.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the plasma cortisol concentration-time curve from 0 to 12 hours (AUEC0-12)

End point title	Area under the plasma cortisol concentration-time curve from O
	to 12 hours (AUECO-12)

End point description:

To evaluate the pharmacodynamic (PD) of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline plasma cortisol concentration was determined during the washout period within 1-7 days before the first dose of study treatment. Change from baseline was calculated as the differences between the post-dose value at each time-point and baseline. The PD analysis set was used to evaluate this endpoint, which included all subjects for whom plasma cortisol AUECO-12 was calculated at baseline and post-baseline, and who had no major protocol deviations considered to impact on the analysis of the PD data (e.g., disallowed medication, poor treatment compliance).

End point type	Secondary
End point timeframe:	
Pre-dose (baseline) and 2, 4, 6, 8, 12 hours post-dose at Day 15	

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	16	12	
Units: h*ng/mL			
geometric mean (geometric coefficient of variation)	602.7 (± 45.0)	891.4 (± 49.0)	

Statistical analyses

Statistical analysis title

Plasma cortisol level on Day 15

Statistical analysis description:		
Relative change from baseline		
Comparison groups	12-14 years v 15-17 years	
Number of subjects included in analysis	28	
Analysis specification	Pre-specified	
Analysis type		
Parameter estimate	Geometric least squares mean	
Point estimate	0.92	
Confidence interval		
level	90 %	
sides	2-sided	
lower limit	0.79	
upper limit	1.06	
Variability estimate	Standard error of the mean	
Dispersion value	0.08	

Secondary: Change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15

End point title	Change from baseline in morning trough forced expiratory
	volume in 1 second (FEV1) on Day 15

End point description:

To evaluate the PD of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline was defined as the mean of the two measured values before first study drug administration (-45 minutes and -15 minutes) on Day 1 and trough value was defined as the mean of the two measurements 30 minutes apart (23 hours after last dose) pre-dose on Day 15. This could be performed either at home (or other safe location of the subject's choice) or at the study site. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.

End point type

Secondary

End point timeframe:

Day 1 (baseline) and at Day 15 (pre-dose)

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	16	15	
Units: Liter			
arithmetic mean (standard deviation)	0.0388 (± 0.2069)	-0.1346 (± 0.5038)	

Statistical analyses

Statistical analysis title	FEV1 on Day 15	
Statistical analysis description:		
Change from baseline		
Comparison groups	12-14 years v 15-17 years	

Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least squares mean
Point estimate	-0.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.17
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.07

Secondary: Change from baseline in asthma control questionnaire (ACQ-5) on Day 15

Change from baseline in asthma control questionnaire (ACQ-5)
on Day 15

End point description:

To evaluate the PD of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline and Day 15 ACQ-5 scores were defined as the mean of the five question responses collected before velsecorat administration at each of Day 1 and Day 15, respectively. Change from baseline was defined as the Day 15 score minus baseline score. The validated ACQ-5 measures both the adequacy of asthma control and changes in asthma control. The questionnaire had 5 items; each item is scored on a scale of 0 to 6, where lower scores corresponds better asthma control and higher scores represents more severe impairment/symptoms. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.

End point type	Secondary
End point timeframe:	
At Day 15	

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	19	15	
Units: Score on scale			
arithmetic mean (standard deviation)	-0.23 (± 0.637)	-0.20 (± 0.994)	

Statistical analyses

Statistical analysis title	ACQ-5 score on Day 15		
Statistical analysis description:			
Change from baseline			
Comparison groups	12-14 years v 15-17 years		

Number of subjects included in analysis	34
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Least squares mean
Point estimate	-0.21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.41
upper limit	-0.02
Variability estimate	Standard error of the mean
Dispersion value	0.11

Secondary: Number of subjects with adverse events (AEs)

End point title

Number of subjects with adverse events (AEs)

End point description:

To evaluate the tolerability and safety of inhaled velsecorat. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.

End point type	Secondary
End point timeframe:	
Day 1 until follow-up (7-14 days)	

End point values	12-14 years	15-17 years	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	20	16	
Units: Subjects			
Any AE	1	3	
Any AE with outcome of Death	0	0	
Any serious adverse event	0	0	
Any AE leading to discontinuation of study drug	0	0	
Any AE leading to withdrawal from study	0	0	

Statistical analyses

No statistical analyses for this end point

Adverse events informat	ion
Timeframe for reporting advers	se events:
Day 1 until follow-up (7-14 day	(S)
Assessment type	Non-systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	21.0
Reporting groups	
Reporting group title	15-17 years
Reporting group description:	- · ·
Subjects received oral inhalatic days.	on of velsecorat (360 μg_{i} delivered dose, via DPI) once daily for 15 to 16
Reporting group title	12-14 years
Reporting group description:	

Subjects received oral inhalation of velsecorat (360 μ g, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days.

Serious adverse events	15-17 years	12-14 years	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	15-17 years	12-14 years	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 16 (18.75%)	1 / 20 (5.00%)	
Injury, poisoning and procedural complications			
Muscle injury			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			
Food allergy			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Infections and infestations			

Acute sinusitis subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 20 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 20 (0.00%) 0	

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 October 2019	Inclusion criteria # 3 and # 7 updated to clarify that asthma treatment may be daily or intermittently, and to adjust the body mass index inclusion restriction to above the 5th percentile rather than within the 5th and 95th percentile. and exclusion criteria # 1, # 3 and # 4 were updated to exclude subjects with severe obesity including weight-related health problems, and to extend ECG screening exclusion criteria from Visit 1 to Visit 1 or pre-dose Visit 4.
22 April 2020	Removal of reversibility criteria. Deletion of Visit 2. A window of +10 minutes added for the 30-minute post-dose ECG only. Text added allowing subjects to choose an alternate safe location for home nursing visits. Inclusion criterion # 3 updated and included that the subject must have used the monotherapy at least once in the 3 months prior to screening. Screen failures section revised to allow re-screening of screen failure subjects due to not meeting reversibility criteria. Section of sample size determination was revised to increase the flexibility, that 24 eligible subjects should include 11 to 13 subjects in each age group was removed. Addition that ECG collection timing was to occur prior to vital signs when these assessments were performed at the same time. Requirement that the 24 eligible subjects should include 11 to 13 subjects in each age group was removed. Addition that ECG collection timing was to occur prior to vital signs when these assessments were performed at the same time. Requirement that the 24 eligible subjects should include 11 to 13 subjects in each age group was removed. Changes made to clarify PK and PD set.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
	Due to the COVID-19 pandemic further screening was paused in the trial, while ongoing subjects were allowed to continue until study completion. Based on velsecorat safety profile and the mild asthmatic subject population it was deemed safe to re-start screening again on 23-Apr-2020.	23 April 2020

Notes:

Limitations and caveats

None reported